27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
A Phase III trial evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis has met its primary and all key secondary endpoints. 22 October 2021
US clinical-stage drug developer Sio Gene Therapies has presented positive interim data from its ongoing Phase I/II study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis. 22 October 2021
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today posted financial results for the third quarter of 2021, with total revenue of 3,761 million Swedish kronor ($437 million), an increase of 27% compared with the same period a year ago and 29% at constant exchange rates (CER). 22 October 2021
Massachusetts, USA-based biotech Selecta Biosciences today announced a strategic licensing agreement to advance a next-generation IgG protease with Genovis, a Swedish enzyme technology company. 21 October 2021
Pushing forward Japan's effort to locally develop COVID-19 shots, Daiichi Sankyo has announced progress on the development of DS-5670, an mRNA vaccine in Japan, being evaluated against the novel coronavirus infectious disease (COVID-19), including results from a Phase I/II clinical trial. 21 October 2021
UK health technology assessor the National Institute for Heath and Care Excellence (NICE) has recommending the use of Givlaari (givosiran) on the NHS in England as an option for the treatment of acute hepatic porphyria (AHP) in people 12 years and older who have clinically confirmed severe recurrent attacks (four attacks or more within 12 months). 21 October 2021
The US Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment of patients aged six to 11 years with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma. 21 October 2021
Semglee (insulin glargine-yfgn), an insulin glargine biosimilar developed by Indian company Biocon, has been listed as a preferred brand by one of the USA’s largest pharmacy benefit managers, Express Scripts. 21 October 2021
Parisian drugmaker Ipsen has reported total sales of 727 million euros (846 million) in the third quarter, representing growth of 14.9% from the same period of 2020. 21 October 2021
The prevalence of major depressive disorder (MDD) – a highly debilitating condition often known as clinical depression - is expected to increase due to COVID-19-related stress. 21 October 2021
Austrian drug developer Marinomed Biotech has entered a new collaboration and licensing agreement with Chinese drugmaker Luoxin Pharmaceutical Group. 21 October 2021
Looking ahead to the potential implications of Biogen’s landmark approval in Alzheimer’s (AD), industry analyst GlobalData has conducted research into the market potential for a next-generation candidate. 21 October 2021
The US Food and Drug Administration said yesterday that it has taken action to expand the use of a booster dose for COVID-19 vaccines in eligible populations for vaccine developed by Johnson & Johnson and Moderna. 21 October 2021
Dutch biotech VarmX has been awarded up to 17.5 million ($20.4million) from the European Innovation Council (EIC) Accelerator, subject to negotiation, to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001. 21 October 2021
UK and USA-based clinical stage biotech F-star Therapeutics today announced a license and collaboration agreement with Janssen Biotech, a subsidiary of US healthcare giant of Johnson & Johnson. 20 October 2021
The US medicines cost watchdog the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of eculizumab and efgartigimod for the treatment of generalized myasthenia gravis (gMG). 20 October 2021
Biogen’s novel Alzheimer’s (AD) therapy is struggling to clear the launch pad, generating just $300,000 in the first quarter in which it became available. 20 October 2021
Drug price disruptor EQRx has signed a memorandum of understanding (MoU) with the UK’s National Health Service, outlining plans for a long-term partnership to supply medicines. 20 October 2021